These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21262370)

  • 21. Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.
    Douam F; Bobay LM; Maurin G; Fresquet J; Calland N; Maisse C; Durand T; Cosset FL; Féray C; Lavillette D
    J Virol; 2016 Jan; 90(2):992-1008. PubMed ID: 26537674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.
    Machida K; Kondo Y; Huang JY; Chen YC; Cheng KT; Keck Z; Foung S; Dubuisson J; Sung VM; Lai MM
    J Virol; 2008 Jul; 82(13):6711-20. PubMed ID: 18417597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
    Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
    Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells.
    Ploss A; Evans MJ; Gaysinskaya VA; Panis M; You H; de Jong YP; Rice CM
    Nature; 2009 Feb; 457(7231):882-6. PubMed ID: 19182773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis.
    Codran A; Royer C; Jaeck D; Bastien-Valle M; Baumert TF; Kieny MP; Pereira CA; Martin JP
    J Gen Virol; 2006 Sep; 87(Pt 9):2583-2593. PubMed ID: 16894197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.
    Zhang J; Randall G; Higginbottom A; Monk P; Rice CM; McKeating JA
    J Virol; 2004 Feb; 78(3):1448-55. PubMed ID: 14722300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
    Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
    Prentoe J; Bukh J
    Front Immunol; 2018; 9():2146. PubMed ID: 30319614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COPII cargo claudin-12 promotes hepatitis C virus entry.
    Huang J; Yin P; Zhang L
    J Viral Hepat; 2019 Feb; 26(2):308-312. PubMed ID: 30339745
    [No Abstract]   [Full Text] [Related]  

  • 31. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus utilizes VLDLR as a novel entry pathway.
    Ujino S; Nishitsuji H; Hishiki T; Sugiyama K; Takaku H; Shimotohno K
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):188-93. PubMed ID: 26699506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.
    Bartosch B; Dubuisson J; Cosset FL
    J Exp Med; 2003 Mar; 197(5):633-42. PubMed ID: 12615904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.
    Schwarz AK; Grove J; Hu K; Mee CJ; Balfe P; McKeating JA
    J Virol; 2009 Dec; 83(23):12407-14. PubMed ID: 19776133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection.
    Liu S; Zhang Q; Shao X; Wang W; Zhang C; Jin Z
    Int Immunopharmacol; 2017 Sep; 50():87-94. PubMed ID: 28644966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.
    Catanese MT; Graziani R; von Hahn T; Moreau M; Huby T; Paonessa G; Santini C; Luzzago A; Rice CM; Cortese R; Vitelli A; Nicosia A
    J Virol; 2007 Aug; 81(15):8063-71. PubMed ID: 17507483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry.
    Hikosaka K; Noritake H; Kimura W; Sultana N; Sharkar MT; Tagawa Y; Uezato T; Kobayashi Y; Wakita T; Miura N
    Biomed Res; 2011 Apr; 32(2):143-50. PubMed ID: 21551950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
    Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
    Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.
    Nguyen LP; Park C; Luong TTD; Park EM; Choi DH; Han KM; Mai HN; Nguyen HC; Lim YS; Hwang SB
    Sci Rep; 2019 May; 9(1):7288. PubMed ID: 31086268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.
    Deest M; Westhaus S; Steinmann E; Manns MP; von Hahn T; Ciesek S
    Antiviral Res; 2014 Jan; 101():37-44. PubMed ID: 24211330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.